ORTHOCELL LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.365 AUD | +1.39% |
|
-2.67% | -10.98% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Orthocell Limited is an Australia-based regenerative medicine company. The Company is focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries. Its portfolio of products includes Striate+, Remplir, and OrthoACI. Striate+ is a sterile, resorbable collagen membrane used for guided bone and tissue regeneration in dental applications. Remplir is a collagen scaffold used in peripheral nerve repair. OrthoACI or autologous chondrocyte implantation is used for the treatment of articular cartilage defects in the knee and ankle. OrthoACI uses the patientâs own healthy cartilage cells called chondrocytes to assist the regeneration of damaged cartilage. The Company is engaged in the development of its tendon cell therapy in the United States. Its autologous tendon therapy is an advanced injectable cellular therapy for the treatment of chronic tendon injuries.
Calendar
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -10.98% | 50.02M | |
| +4.85% | 212B | |
| +9.86% | 188B | |
| +31.11% | 157B | |
| +34.08% | 114B | |
| +1.90% | 64.01B | |
| +19.45% | 54.88B | |
| +1.63% | 48.83B | |
| -3.12% | 39.3B | |
| +1.93% | 35.97B |
- Stock Market
- Equities
- OCC Stock
- News Orthocell Limited
- Orthocell Begins Comparator Study for Product Marketing Initiatives
